125 related articles for article (PubMed ID: 606431)
1. Phosphate and 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
Davison AM; Peacock M; Walker GS; Marshall DH; McLaughlin MS; Robinson PJ
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():91s-99s. PubMed ID: 606431
[No Abstract] [Full Text] [Related]
2. Calcium and phosphate metabolism in chronic renal failure, with particular reference to the effect of 1 alpha-hydroxyvitamin D3.
Madsen S
Acta Med Scand Suppl; 1980; 638():3-120. PubMed ID: 6929650
[No Abstract] [Full Text] [Related]
3. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
Peacock M; Davison AM; Walker GS
Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
[No Abstract] [Full Text] [Related]
4. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alpha-hydroxyvitamin D3.
Peacock M; Aaron JE; Walker GS; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():73s-81s. PubMed ID: 606428
[No Abstract] [Full Text] [Related]
5. Prophylactic 1alpha-hydroxyvitamin D3 therapy in haemodialysis patients.
Walker GS; Peacock M; Aaron J; Robinson PJ; Davison AM
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():125s-130s. PubMed ID: 606410
[TBL] [Abstract][Full Text] [Related]
6. Effects of 1alpha-hydroxyvitamin D3 on serum calcium and immunoreactive parathyroid hormone in patients with chronic renal insufficiency.
Pietrek J; Kokot F; Kuska J
Int Urol Nephrol; 1978; 10(2):153-60. PubMed ID: 700946
[TBL] [Abstract][Full Text] [Related]
7. Effects of 25-hydroxycholecalciferol on calcium metabolism in chronic renal failure.
Letteri JM; Kleinman LM; Ellis KN; Caselnova R; Akhtar M; Cohn SH
Adv Exp Med Biol; 1977; 81():591-601. PubMed ID: 899943
[No Abstract] [Full Text] [Related]
8. 1alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in renal bone disease.
Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; De Luca HF
Calcif Tissue Res; 1976 Aug; 21 Suppl():226-35. PubMed ID: 782662
[No Abstract] [Full Text] [Related]
9. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
Massry SG; Goldstein DA; Malluche HH
Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
[No Abstract] [Full Text] [Related]
10. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
11. The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.
Bordier P; Zingraff J; Gueris J; Jungers P; Marie P; Pechet M; Rasmussen H
Am J Med; 1978 Jan; 64(1):101-7. PubMed ID: 623125
[TBL] [Abstract][Full Text] [Related]
12. Effect of 1alpha-hydroxyvitamin D3 on parathyroid function in patients with chronic renal failure.
Nielsen HE; Christensen MS; Melsen F; Rømer FK; Hansen HE
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():67s-72s. PubMed ID: 606427
[TBL] [Abstract][Full Text] [Related]
13. Short-term effects of varying doses of 1 alpha-hydroxyvitamin D3 on blood and urine chemistry and calcium absorption of osteoporotic patients.
Lindholm TS; Sevastikoglou JA; Lindgren U
Clin Orthop Relat Res; 1978 Sep; (135):226-31. PubMed ID: 709935
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical, biochemical and skeletal responses to 1alpha-hydroxyvitamin D3 in renal bone disease.
Kanis JA; Earnshaw M; Henderson RG; Heynen G; Ledingham JG; Naik RB; Oliver DO; Russell RG; Smith R; Wilkinson RH; Woods CG
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():45s-50s. PubMed ID: 606424
[TBL] [Abstract][Full Text] [Related]
15. The action of 1alphahydroxy vitamin D3 and phosphate supplements in hypophosphataemic osteomalacia.
Peacock M; Aaron JE; Heyburn PJ; Nordin BE
Adv Exp Med Biol; 1977; 81():431-40. PubMed ID: 899935
[No Abstract] [Full Text] [Related]
16. Influence of 1 alpha-hydroxy vitamin D3 (0.25 micrograms/day) and calcium carbonate on patients with chronic renal failure at the predialytic stage.
Okada K; Nagura Y; Takahashi S; Hatano M
Nihon Jinzo Gakkai Shi; 1989 Jun; 31(6):657-60. PubMed ID: 2795995
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
[No Abstract] [Full Text] [Related]
18. The effect of 1alpha-hydroxyvitamin D3 in patients with chronic renal failure, with particular emphasis on the renal handling of phosphate.
Madsen S; Olgaard K
Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():85s-89s. PubMed ID: 606430
[No Abstract] [Full Text] [Related]
19. Association of conjunctival and corneal calcification with vascular calcification in dialysis patients.
Seyahi N; Altiparmak MR; Kahveci A; Yetik H; Kanberoglu K; Serdengecti K; Ataman R; Erek E
Am J Kidney Dis; 2005 Mar; 45(3):550-6. PubMed ID: 15754277
[TBL] [Abstract][Full Text] [Related]
20. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
